Background: Global guidelines recommend preexposure prophylaxis (PrEP) for individuals with substantial human immunodeficiency virus (HIV) risk. Data on PrEP uptake in sub-Saharan Africa outside of clinical trials are limited. We report on "early adopters" of PrEP in the Sustainable East Africa Research in Community Health (SEARCH) study in rural Uganda and Kenya. Methods: After community mobilization and PrEP education, population-based HIV testing was conducted. HIV-uninfected adults were offered PrEP based on an empirically derived HIV risk score or self-identified HIV risk (if not identified by score). Using logistic regression, we analyzed predictors of early PrEP adoption (starting PrEP within 30 days vs delayed/no start) among adults identified for PrEP. Results: Of 21212 HIV-uninfected adults in 5 communities, 4064 were identified for PrEP (2991 by empiric risk score, 1073 by self-identified risk). Seven hundred and thirty nine individuals startedPrEP within 30 days (11% of those identified by risk score; 39% of self-identified); 77% on the same day. Among adults identified by risk score, predictors of early adoption included male sex (adjusted odds ratio 1.53; 95% confidence interval, 1.09-2.15), polygamy (1.92; 1.27-2.90), serodiscordant spouse (3.89; 1.18-12.76), self-perceived HIV risk (1.66; 1.28-2.14), and testing at health campaign versus home (5.24; 3.33-8.26). Among individuals who self-identified for PrEP, predictors of early adoption included older age (2.30; 1.29-4.08) and serodiscordance (2.61; 1.01-6.76). Conclusions: Implementation of PrEP incorporating a population-based empiric risk score, self-identified risk, and rapid initiation, is feasible in rural East Africa. Strategies are needed to overcome barriers to PrEP uptake, particularly among women and youth. Clinical Trials Registration: NCT01864603.
RCT Entities:
Background: Global guidelines recommend preexposure prophylaxis (PrEP) for individuals with substantial human immunodeficiency virus (HIV) risk. Data on PrEP uptake in sub-Saharan Africa outside of clinical trials are limited. We report on "early adopters" of PrEP in the Sustainable East Africa Research in Community Health (SEARCH) study in rural Uganda and Kenya. Methods: After community mobilization and PrEP education, population-based HIV testing was conducted. HIV-uninfected adults were offered PrEP based on an empirically derived HIV risk score or self-identified HIV risk (if not identified by score). Using logistic regression, we analyzed predictors of early PrEP adoption (starting PrEP within 30 days vs delayed/no start) among adults identified for PrEP. Results: Of 21212 HIV-uninfected adults in 5 communities, 4064 were identified for PrEP (2991 by empiric risk score, 1073 by self-identified risk). Seven hundred and thirty nine individuals started PrEP within 30 days (11% of those identified by risk score; 39% of self-identified); 77% on the same day. Among adults identified by risk score, predictors of early adoption included male sex (adjusted odds ratio 1.53; 95% confidence interval, 1.09-2.15), polygamy (1.92; 1.27-2.90), serodiscordant spouse (3.89; 1.18-12.76), self-perceived HIV risk (1.66; 1.28-2.14), and testing at health campaign versus home (5.24; 3.33-8.26). Among individuals who self-identified for PrEP, predictors of early adoption included older age (2.30; 1.29-4.08) and serodiscordance (2.61; 1.01-6.76). Conclusions: Implementation of PrEP incorporating a population-based empiric risk score, self-identified risk, and rapid initiation, is feasible in rural East Africa. Strategies are needed to overcome barriers to PrEP uptake, particularly among women and youth. Clinical Trials Registration: NCT01864603.
Authors: Jillian Pintye; Alison L Drake; John Kinuthia; Jennifer A Unger; Daniel Matemo; Renee A Heffron; Ruanne V Barnabas; Pamela Kohler; R Scott McClelland; Grace John-Stewart Journal: Clin Infect Dis Date: 2017-03-15 Impact factor: 9.079
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Christina P Lindan; Andrew Anglemyer; Wolfgang Hladik; Joseph Barker; George Lubwama; George Rutherford; John Ssenkusu; Alex Opio; James Campbell Journal: Int J STD AIDS Date: 2014-06-26 Impact factor: 1.359
Authors: Jennifer E Balkus; Elizabeth Brown; Thesla Palanee; Gonasagrie Nair; Zakir Gafoor; Jingyang Zhang; Barbra A Richardson; Zvavahera M Chirenje; Jeanne M Marrazzo; Jared M Baeten Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Gabriel Chamie; Tamara D Clark; Jane Kabami; Kevin Kadede; Emmanuel Ssemmondo; Rachel Steinfeld; Geoff Lavoy; Dalsone Kwarisiima; Norton Sang; Vivek Jain; Harsha Thirumurthy; Teri Liegler; Laura B Balzer; Maya L Petersen; Craig R Cohen; Elizabeth A Bukusi; Moses R Kamya; Diane V Havlir; Edwin D Charlebois Journal: Lancet HIV Date: 2016-01-26 Impact factor: 12.767
Authors: Carol S Camlin; Catherine A Koss; Monica Getahun; Lawrence Owino; Harriet Itiakorit; Cecilia Akatukwasa; Irene Maeri; Robert Bakanoma; Anjeline Onyango; Frederick Atwine; James Ayieko; Jane Kabami; Florence Mwangwa; Mucunguzi Atukunda; Asiphas Owaraganise; Dalsone Kwarisiima; Norton Sang; Elizabeth A Bukusi; Moses R Kamya; Maya L Petersen; Craig R Cohen; Edwin D Charlebois; Diane V Havlir Journal: AIDS Behav Date: 2020-07
Authors: Laura B Balzer; Diane V Havlir; Moses R Kamya; Gabriel Chamie; Edwin D Charlebois; Tamara D Clark; Catherine A Koss; Dalsone Kwarisiima; James Ayieko; Norton Sang; Jane Kabami; Mucunguzi Atukunda; Vivek Jain; Carol S Camlin; Craig R Cohen; Elizabeth A Bukusi; Mark Van Der Laan; Maya L Petersen Journal: Clin Infect Dis Date: 2020-12-03 Impact factor: 20.999
Authors: William Ddaaki; Susanne Strömdahl; Ping Teresa Yeh; Anna Mia Ekström; Caitlin E Kennedy; Joseph G Rosen; Jade Jackson; Neema Nakyanjo; Joseph Kagaayi; Godfrey Kigozi; Gertrude Nakigozi; M Kathryn Grabowski; Larry W Chang; Steven J Reynolds; Fred Nalugoda Journal: AIDS Behav Date: 2021-07-09
Authors: Gideon Loevinsohn; Godfrey Kigozi; Joseph Kagaayi; Maria J Wawer; Fred Nalugoda; Larry W Chang; Thomas C Quinn; David Serwadda; Steven J Reynolds; Lisa Nelson; Lisa Mills; Stella Alamo; Gertrude Nakigozi; Geoffrey Kabuye; Robert Ssekubugu; Aaron A R Tobian; Ronald H Gray; M Kathryn Grabowski Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999
Authors: Anna Bershteyn; Monisha Sharma; Adam N Akullian; Kathryn Peebles; Supriya Sarkar; R Scott Braithwaite; Edinah Mudimu Journal: J Int AIDS Soc Date: 2020-06 Impact factor: 5.396
Authors: Joseph Kagaayi; James Batte; Hadijja Nakawooya; Boniface Kigozi; Gertrude Nakigozi; Susanne Strömdahl; Anna Mia Ekström; Larry W Chang; Ron Gray; Steven J Reynolds; Patrick Komaketch; Stella Alamo; David Serwadda Journal: J Int AIDS Soc Date: 2020-08 Impact factor: 5.396